DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES

该项目的长期目标仍然是开发新的代理商 用于治疗人类癌症。 由于大多数，如果不是全部， 目前用于治疗人类癌症的核苷必须 磷酸化为活性形式，我们计划进行一些详细的研究 这些酶是已知的进行这种激活的酶。 脱氧胞嘧啶 激酶是启动这一过程的主要但不是唯一的酶 激活过程，所以我们计划专注于它，与博士合作。 唐娜·S密歇根大学的Shewach说。 我们计划准备一个 一系列的化合物，重点是它们激活酶， 抗肿瘤选择性。 我们还计划检查我们收集的核苷三磷酸， 端粒酶抑制剂，端粒酶是一种在人体内被激活的DNA聚合酶 癌的 这些研究将显示我们手头上或容易获得的三磷酸盐 生成，并将为我们提供SAR信息， 设计新的化合物， 酶，这似乎是一个重要的新的目标，可以化疗。

The long-term goal of this project remains the development of new agents for the treatment of human cancers. Since most, if not all, of the nucleosides currently in use for the treatment of human cancers must phosphorylated to their active forms, we plan to investigate in some detail the enzymes that are known to carry out this activation. Deoxycytidine kinase is the primary, but not the only, enzyme that initiates this activation process, so we plan to focus on it, in collaboration with Dr. Donna S. Shewach of the University of michigan. We plan to prepare a broad series of compounds with a focus on them activating enzymes as well as their antitumor selectivity. We also plan to examine our collection of nucleoside triphosphates as inhibitors of telomerase, a DNA polymerase which is activated in human cancers. The studies will show triphosphates we have on hand or easily generate, and will provide us with SAR information that will be used in designing new compounds that will be more specific inhibitors for this enzyme, which appears to be an important new target for can chemotherapy.